文献速递妇科肿瘤

错配修复缺陷的不同机制界定子宫内膜癌抗PD-1免疫治疗两种应答模式

Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
PubMed 文献 · Cancer Discov · 2023-01-01

在24例错配修复缺陷(MMRd)子宫内膜癌患者中开展帕博利珠单抗II期临床试验,突变型MMRd(6例)的缓解率和生存优于表观遗传型MMRd(18例),且两者分别与CD8+ T细胞和CD16+ NK细胞免疫相关,提示按MMRd机制分类可能辅助免疫治疗决策。

要点

  • 突变型MMRd(6例)缓解率更高、生存更长,优于表观遗传型MMRd(18例)。
  • 突变负荷在突变型MMRd更高,但在各MMRd类别内与ICB应答不相关。
  • 治疗前JAK1突变与帕博利珠单抗原发耐药不相关。

核心结论

  • MMRd的分子机制与子宫内膜癌抗PD-1免疫治疗应答相关,按MMRd机制分类可能辅助癌症免疫治疗的临床决策。

研究设计与样本

  • 在24例MMRd子宫内膜癌患者中开展帕博利珠单抗(PD-1抑制剂)II期临床试验(NCT02899793)。
  • 按MMRd机制分为突变型MMRd(6例)和表观遗传型MMRd(18例)两组。
  • 采用治疗前肿瘤测序及纵向外周免疫细胞单细胞RNA测序进行分析。

主要发现

  • 突变型MMRd患者(6例)缓解率高于表观遗传型MMRd患者(18例),生存也长于后者。
  • 突变型MMRd肿瘤的突变负荷高于表观遗传型MMRd肿瘤;但在各MMRd类别内,突变负荷与ICB应答不相关。
  • 治疗前JAK1突变与帕博利珠单抗原发耐药不相关。
  • 纵向外周免疫细胞单细胞RNA测序显示,突变型与表观遗传型MMRd癌症的抗肿瘤免疫模式形成对比。
  • 效应CD8+ T细胞与突变型MMRd肿瘤消退相关,而活化CD16+ NK细胞与ICB应答的表观遗传型MMRd肿瘤相关。

临床怎么用

  • 作者认为,按MMRd机制对肿瘤进行分类可能为癌症免疫治疗的临床决策提供信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Mismatch repair-deficient (MMRd) cancers have varied responses to immune-checkpoint blockade (ICB). We conducted a phase II clinical trial of the PD-1 inhibitor pembrolizumab in 24 patients with MMRd endometrial cancer (NCT02899793). Patients with mutational MMRd tumors (6 patients) had higher response rates and longer survival than those with epigenetic MMRd tumors (18 patients). Mutation burden was higher in tumors with mutational MMRd compared with epigenetic MMRd; however, within each category of MMRd, mutation burden was not correlated with ICB response. Pretreatment JAK1 mutations were not associated with primary resistance to pembrolizumab. Longitudinal single-cell RNA-seq of circulating immune cells revealed contrasting modes of antitumor immunity for mutational versus epigenetic MMRd cancers. Whereas effector CD8+ T cells correlated with regression of mutational MMRd tumors, activated CD16+ NK cells were associated with ICB-responsive epigenetic MMRd tumors. These data highlight the interplay between tumor-intrinsic and tumor-extrinsic factors that influence ICB response. SIGNIFICANCE: The molecular mechanism of MMRd is associated with response to anti-PD-1 immunotherapy in endometrial carcinoma. Tumors with epigenetic MMRd or mutational MMRd are correlated with NK cell or CD8+ T cell-driven immunity, respectively. Classifying tumors by the mechanism of MMRd may inform clinical decision-making regarding cancer immunotherapy. This article is highlighted in the In This Issue feature, p. 247.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Chow RD, Michaels T, Bellone S, et al. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma. Cancer Discov. 2023. PMID: 36301137. doi:10.1158/2159-8290.CD-22-0686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。